ABCAM Plc
01 May 2008


For immediate release                                01 May 2008


                                   ABCAM PLC
                          ("Abcam" or "the Company")

                                 Trading Update


The Board of Abcam plc (AIM: ABC), the rapidly growing bioscience company that
markets antibodies via its own online catalogue, is pleased to provide
shareholders with a trading update.


Sales growth, so far, in the second half of the financial year has been
particularly strong as a result of higher volumes, improved pricing and
beneficial exchange rate movements, particularly in the Euro/£ rate. As a result
sales are now expected to be ahead of market expectations and the outlook for
the profit for the full year to 30 June 2008 has improved significantly.


Jonathan Milner, Abcam's Chief Executive Officer, said: "We have been
particularly pleased by the momentum in our sales growth across all of our
geographies. This momentum is a reflection of the growth in the research
antibody market, of the strength of the Abcam brand and of our leadership in the
selection of antibodies of particular scientific interest."

For further information please contact:

Abcam                                                       + 44 (0) 1223 696000
Jonathan Milner, Chief Executive Officer
Jeff Iliffe, Chief Financial Officer
www.abcam.com

Numis Securities                                           + 44 (0) 20 7776 1500
James Black/Nick Westlake

Buchanan Communications                                    + 44 (0) 20 7466 5000
Mark Court / Mary-Jane Johnson



Notes for editors:

About Abcam plc

Abcam is a producer and distributor of research-grade antibodies headquartered
in Cambridge, UK, with a US office located in Cambridge, Massachusetts and a
Japanese office in Tokyo. Abcam was admitted to AIM in November 2005 and trades
under the ticker symbol ABC.  The Company produces and distributes its own and
third party produced antibodies to academic and commercial users throughout the
world with product information provided and ordering available through the
Company's website, www.abcam.com. The antibodies are sold under the Abcam brand
name. The Company's vision is to build the largest online antibody resource in
the world while also ensuring that the antibodies are of high quality and
commercially viable. Abcam now has an online catalogue of approximately 42,000
products, most of which are antibodies, from over 200 suppliers supported by
up-to-date and detailed technical data sheets, which are created by the Company.
The Company currently employs 176 staff in its three operating companies.




                      This information is provided by RNS
            The company news service from the London Stock Exchange

• News Channel